CY1111628T1 - Υποκατεστημενες ενωσεις δικυκλολακταμης - Google Patents

Υποκατεστημενες ενωσεις δικυκλολακταμης

Info

Publication number
CY1111628T1
CY1111628T1 CY20111100479T CY111100479T CY1111628T1 CY 1111628 T1 CY1111628 T1 CY 1111628T1 CY 20111100479 T CY20111100479 T CY 20111100479T CY 111100479 T CY111100479 T CY 111100479T CY 1111628 T1 CY1111628 T1 CY 1111628T1
Authority
CY
Cyprus
Prior art keywords
compounds
bicyclactam
substituted
compositions
formula
Prior art date
Application number
CY20111100479T
Other languages
English (en)
Inventor
Robert Lee Dow
Michael John Munchhof
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of CY1111628T1 publication Critical patent/CY1111628T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Η εφεύρεση παρέχει ενώσεις του τύπου (I) και φαρμακευτικώς αποδεκτό άλας αυτών, όπου R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, Α, Ζ και R7 είναι όπως περιγράφεται εδώ, συνθέσεις αυτών και χρήσεις αυτών.
CY20111100479T 2007-08-02 2011-05-17 Υποκατεστημενες ενωσεις δικυκλολακταμης CY1111628T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02
EP08788942A EP2185567B1 (en) 2007-08-02 2008-07-22 Substituted bicyclolactam compounds

Publications (1)

Publication Number Publication Date
CY1111628T1 true CY1111628T1 (el) 2015-10-07

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100479T CY1111628T1 (el) 2007-08-02 2011-05-17 Υποκατεστημενες ενωσεις δικυκλολακταμης

Country Status (34)

Country Link
US (2) US20090036425A1 (el)
EP (1) EP2185567B1 (el)
JP (1) JP4629808B2 (el)
KR (1) KR20100032443A (el)
CN (1) CN101772504A (el)
AP (1) AP2010005163A0 (el)
AR (1) AR067780A1 (el)
AT (1) ATE502948T1 (el)
AU (1) AU2008281545B2 (el)
BR (1) BRPI0815067A2 (el)
CA (1) CA2695291C (el)
CL (1) CL2008002227A1 (el)
CO (1) CO6251365A2 (el)
CR (1) CR11223A (el)
CY (1) CY1111628T1 (el)
DE (1) DE602008005757D1 (el)
DK (1) DK2185567T3 (el)
DO (1) DOP2010000046A (el)
EA (1) EA201000050A1 (el)
EC (1) ECSP109932A (el)
ES (1) ES2361716T3 (el)
HN (1) HN2008001191A (el)
HR (1) HRP20110335T1 (el)
MA (1) MA31580B1 (el)
PA (1) PA8791601A1 (el)
PE (1) PE20090897A1 (el)
PL (1) PL2185567T3 (el)
PT (1) PT2185567E (el)
SI (1) SI2185567T1 (el)
TN (1) TN2010000053A1 (el)
TW (1) TWI356059B (el)
UA (1) UA94833C2 (el)
WO (1) WO2009016462A2 (el)
ZA (1) ZA201000255B (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
JP2009520786A (ja) 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
EP2404905A1 (en) 2006-03-31 2012-01-11 Novartis AG New compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
KR20090024811A (ko) 2006-06-23 2009-03-09 아보트 러보러터리즈 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2010086820A1 (en) * 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2010089685A1 (en) * 2009-02-03 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2393811A1 (en) * 2009-02-04 2011-12-14 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
MX2012010772A (es) 2010-03-19 2012-11-06 Pfizer Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3,5]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina.
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
PL2632925T3 (pl) 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
WO2012112364A1 (en) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
WO2012122075A1 (en) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
CN106117205B (zh) 2011-04-22 2018-09-21 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
NZ716420A (en) 2011-05-10 2017-05-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
JP5844456B2 (ja) * 2011-05-20 2016-01-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物
NO3175985T3 (el) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013068439A1 (en) * 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
CA2853024C (en) 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
WO2013119040A1 (en) 2012-02-07 2013-08-15 Kainos Medicine, Inc. Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2013150416A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2842938A4 (en) * 2012-04-25 2015-12-23 Korea Res Inst Chem Tech NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CN104411690A (zh) 2012-06-20 2015-03-11 霍夫曼-拉罗奇有限公司 作为lpar拮抗剂的取代的吡唑化合物
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9550793B2 (en) 2012-10-03 2017-01-24 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
EA031114B1 (ru) * 2012-11-23 2018-11-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи ПРОИЗВОДНЫЕ ДИГИДРОПИРИМИДО[5,4-f]ОКСАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ДИАЦИЛГЛИЦЕРИН АЦИЛТРАНСФЕРАЗЫ
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (en) * 2013-03-15 2014-09-18 Intervet International B.V. Pyridine derivatives as dgat-1 inhibitors
CN104418866B (zh) 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
CA2926568C (en) 2013-10-09 2017-09-05 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
EP3126330B1 (en) 2014-04-04 2019-02-27 Pfizer Inc Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2016013329A (es) 2014-04-10 2017-01-26 Pfizer 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
CA2987179C (en) 2015-05-29 2020-08-25 Pfizer Inc. Heterocyclic compounds as inhibitors of vanin-1 enzyme
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
CA2995153A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
EP3858825A1 (en) 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP6503515B2 (ja) 2015-12-29 2019-04-17 ファイザー・インク ケトヘキソキナーゼ阻害薬としての置換３−アザビシクロ［３．１．０］ヘキサン
SG11201811161YA (en) 2016-07-14 2019-01-30 Pfizer Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶（ｂｃｋｄｋ）抑制劑及／或降解劑
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427310T1 (de) * 2002-01-18 2009-04-15 Kyorin Seiyaku Kk Kondensierte bicyclische pyrimidinderivate
JP3988830B2 (ja) * 2002-11-22 2007-10-10 日本たばこ産業株式会社 縮合二環式窒素含有複素環
JP2007519605A (ja) * 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2009520786A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン

Also Published As

Publication number Publication date
TW200916471A (en) 2009-04-16
EP2185567B1 (en) 2011-03-23
HN2008001191A (es) 2012-01-17
AU2008281545A1 (en) 2009-02-05
KR20100032443A (ko) 2010-03-25
CO6251365A2 (es) 2011-02-21
CN101772504A (zh) 2010-07-07
TWI356059B (en) 2012-01-11
CA2695291A1 (en) 2009-02-05
MA31580B1 (fr) 2010-08-02
ATE502948T1 (de) 2011-04-15
DE602008005757D1 (de) 2011-05-05
PT2185567E (pt) 2011-05-27
CR11223A (es) 2010-02-04
PL2185567T3 (pl) 2011-07-29
PA8791601A1 (es) 2009-12-16
TN2010000053A1 (fr) 2011-09-26
CA2695291C (en) 2012-04-17
EA201000050A1 (ru) 2010-08-30
HRP20110335T1 (hr) 2011-06-30
CL2008002227A1 (es) 2009-04-17
UA94833C2 (en) 2011-06-10
AU2008281545B2 (en) 2011-12-08
PE20090897A1 (es) 2009-08-06
AR067780A1 (es) 2009-10-21
BRPI0815067A2 (pt) 2015-02-10
SI2185567T1 (sl) 2011-06-30
US20090036425A1 (en) 2009-02-05
DOP2010000046A (es) 2010-03-31
DK2185567T3 (da) 2011-05-16
AP2010005163A0 (en) 2010-02-28
WO2009016462A3 (en) 2009-03-26
ECSP109932A (es) 2010-03-31
JP4629808B2 (ja) 2011-02-09
WO2009016462A2 (en) 2009-02-05
US20090137551A1 (en) 2009-05-28
ZA201000255B (en) 2011-03-30
US7718645B2 (en) 2010-05-18
JP2010535190A (ja) 2010-11-18
ES2361716T3 (es) 2011-06-21
EP2185567A2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1121854T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
ECSP10010722A (es) Compuestos orgánicos
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1109322T1 (el) Παραγωγα προλινης και η χρηση τους ως αναστολεις διπεπτιδυλικης πεπτιδασης iv
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1111830T1 (el) Παραγωγα πυριδινης ως ρυθμιστες υποδοχεων s1p1/edg1
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CY1116399T1 (el) Πυραζολυλαμινοπυριδινες ως αναστολεις της fak
CY1119289T1 (el) Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου
ATE478054T1 (de) Benzimidazolderivate
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
NO20071100L (no) 5-jodtetrazoler
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων
CY1117805T1 (el) Αντιμετωπιση οστεοπορωσης